Plathet rich plasma

PreclinicalBiologic

HHospital Italiano de Buenos Aires

Plathet rich plasma is one of 8 biologic programs targeting Tendinopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TendinopathyActive, not recruiting

TendinopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Tendinopathy

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Aspercreme Warming

AAveritas Pharma, Inc.

Platelet Rich Plasma

3 4

Doryx

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

1 5

Aleve

Jazz Pharmaceuticals

Preclinical

1 6

Naproxen Sodium

Bayer

Preclinical

—7

Glyceryl - Trinitrate

PProcris Pharmaceuticals

Preclinical

1 8

Plathet rich plasma

HHospital Italiano de Buenos Aires

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tendinopathy1 trial

Comparison Between Platelet Rich Plasma and Corticosteroids for the Treatment of Rotator Cuff Tendinopathy

Completed·HHospital Italiano de Buenos Aires·N/A·NCT06150378·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Plathet rich plasma. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plathet rich plasma compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plathet rich plasma. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Italiano de Buenos Aires company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: HHospital Italiano de Buenos Aires

Plathet rich plasma

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tendinopathy1 trial

References

Drug Info

Quick Facts

Related News